LESLIE BROWN: Open Payments
NPI 1952733651 · GRETNA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,211 in 10 payments from 10 companies in 2025. Trend: 2023 $1,496 · 2024 $2,128 · 2025 $1,211
Food & beverage: $1,211
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 1 | $163 |
| Madrigal Pharmaceuticals | 1 | $147 |
| Novo Nordisk Inc | 1 | $123 |
| Gilead Sciences, Inc. | 1 | $121 |
| GENZYME CORPORATION | 1 | $120 |
| AstraZeneca Pharmaceuticals LP | 1 | $115 |
| Corcept Therapeutics | 1 | $115 |
| Lilly USA, LLC | 1 | $107 |
| ViiV Healthcare Company | 1 | $102 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $98 |
Products named: FREESTYLE LIBRE 3, REZDIFFRA, Wegovy, FABRAZYME, AIRSUPRA, Korlym, ZEPBOUND, APRETUDE.
Industry payments across LA — which companies pay providers there.
